Non-Dilutive Funding Guide

November 2018

Questions?
Contact: Harry Arader harader@biostl.org
Table of Contents

NIH BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research ................................................................. 6

NIH SBIR/STTR .................................................................................................................. 7

NIH SBIR/STTR Phase IIb: Continuation of Phase II ................................................................ 8

NIH SBIR: Tools for Cell Line Identification ......................................................................... 9

NIH/NCI Cancer Moonshot Funding Opportunities ................................................................ 10

NIH/NCI SBIR: Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care ............... 11

NIH/NHLBI SBIR/STTR Phase IIb Small Market Award .......................................................... 13

NIH/NIAID Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR) ........................................... 14

NIH/NIAID Resource-Related Projects ............................................................................... 15

NIH/NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement .......................................................... 16

NIH/NINDS CREATE: Bio Optimization and Development Tracks for Biologics ............................ 17

BARDA Broad Agency Announcements .............................................................................. 18

DARPA DSO Office-wide Broad Agency Announcement .......................................................... 20

DOD SBIR/STTR ............................................................................................................... 21

DOD Congressionally Directed Medical Research Programs ...................................................... 22

DOD US Army Medical Research and Materiel Command Broad Agency Announcement for Extramural Medical Research ........................................................................ 23

NSF SBIR/STTR ............................................................................................................... 24
<p>| Grant name                                                                 | Agency     | Concentration | Who can apply      | Solicitation link                                      | LOI       | Grant expiration date | Budget       | Project period |
|----------------------------------------------------------------------------|------------|---------------|--------------------|--------------------------------------------------------|-----------|-----------------------|--------------|----------------|----------------|
| <strong>BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research</strong> | NIH        | Neuroscience  | Industry           | PA-18-870 (STTR), PA-18-871 (SBIR)                     | N/A       | May 7, 2021           | $150k-$1M   | 2-3 years       |
| <strong>SBIR/STTR</strong>                                                              | NIH        | Multiple      | Academia           | PA-18-573, PA-18-574 (SBIR), PA-18-575, PA-18-576 (STTR) | N/A       | April 6, 2019         | $150k-$1M   | 6 mos – 2 yrs   |
| <strong>SBIR/STTR Phase IIb: Continuation of Phase II</strong>                         | NIH        | Multiple      | Academia; Industry | PA-18-573, PA-18-574 (SBIR), PA-18-575, PA-18-576 (STTR) | N/A       | Must apply while under Phase II funding | $1M annually | Up to 3 yrs     |
| <strong>SBIR: Tools for Cell Line Identification</strong>                              | NIH        | Misidentified cell lines | Industry | PA-16-186 (SBIR) R43/R44 | N/A       | April 6, 2019         | $150k-$1M   | 6 mos – 2 yrs   |
| <strong>Emerging Questions in Cancer Systems Biology</strong>                          | NIH/NCI    | Cancer        | Academia; Industry | PAR-16-131 (U01)                                       | 30 days prior | 11/24/2018 | Not limited | 5 yrs          |
| <strong>Dissemination and Implementation Research in Health</strong>                   | NIH/NCI    | Cancer        | Academia; Industry | PAR 16-238 (R01), PAR 16-236 (R21)                     | 30 days prior | 5/8/2019  | Not limited | 5 yrs          |
| <strong>Gene Fusions in Pediatric Sarcomas</strong>                                     | NIH/NCI    | Cancer        | Academia; Industry | PA-16-251 (R01), PA-16-252 (R21)                       | N/A       | 5/8/2019              | Not limited | 5 yrs          |
| <strong>Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions</strong> | NIH/NCI    | Cancer        | Academia; Industry | PAR-16-202 (R01), PAR-16-201 (R21)                     | N/A       | 6/14/2019             | Not limited | 5 yrs          |</p>
<table>
<thead>
<tr>
<th>Grant name</th>
<th>Agency</th>
<th>Concentration</th>
<th>Who can apply</th>
<th>Solicitation link</th>
<th>LOI</th>
<th>Grant expiration date</th>
<th>Budget</th>
<th>Project period</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Cancer Moonshot Funding Opportunities</strong></td>
<td>NIH/NCI</td>
<td>Cancer</td>
<td>Academia; Industry</td>
<td>PAR-16-228 (R01)</td>
<td>N/A</td>
<td>9/8/2019</td>
<td>Not limited</td>
<td>5 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PAR-16-229 (R21)</td>
<td></td>
<td></td>
<td>$275k DC/2yr</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Research Projects to Improve Applicability of Mammalian Models for Translational Research</strong></td>
<td>NIH/NCI</td>
<td>Cancer</td>
<td>Academia; Industry</td>
<td>Collaborative: PAR-17-244 (RO1)</td>
<td>N/A</td>
<td>5/8/2020</td>
<td>$450k DC/yr</td>
<td>5 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>General: PAR-17-245 (RO1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SBIR/STTR Phase IIb Small Market Award</strong></td>
<td>NIH/NHLBI</td>
<td>Multiple</td>
<td>Academia; Industry</td>
<td>RFA-HL-19-018</td>
<td>Suggested</td>
<td>July 10, 2020</td>
<td>$3M</td>
<td>3 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR)</strong></td>
<td>NIH/NIAID</td>
<td>MedTech; Biotech</td>
<td>Industry</td>
<td>PA-18-525</td>
<td>N/A</td>
<td>January 6, 2021</td>
<td>$300k-$1M</td>
<td>2-3 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Resource-Related Projects</strong></td>
<td>NIH/NIAID</td>
<td>Multiple</td>
<td>Industry</td>
<td>PAR-16-412</td>
<td>Suggested</td>
<td>September 8, 2019</td>
<td>Unlimited</td>
<td>Up to 5 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>SBIR Phase II Clinical Trial Implementation Cooperative Agreement</strong></td>
<td>NIH/NIAID</td>
<td>Clinical trials</td>
<td>Industry</td>
<td>PAR-18-632</td>
<td>30 days prior</td>
<td>January 14, 2021</td>
<td>$150k-$1M</td>
<td>1-3 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CREATE: Bio Optimization and Development Tracks for Biologics</strong></td>
<td>NIH/NINDS</td>
<td>Biotech; biologics</td>
<td>Academia; Industry</td>
<td>Optimization: PAR-17-456 (U01)</td>
<td>N/A</td>
<td>September 8, 2020</td>
<td>$1-4M</td>
<td>Up to 5 yrs</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PAR-17-457 (U44/SBIR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Development: PAR-18-542 (U01)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>PAR-18-543 (U44/SBIR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant name</td>
<td>Agency</td>
<td>Concentration</td>
<td>Who can apply</td>
<td>Solicitation link</td>
<td>LOI</td>
<td>Grant expiration date</td>
<td>Budget</td>
<td>Project period</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------</td>
<td>-------------------------</td>
<td>---------------</td>
<td>------------------------</td>
<td>--------------------------------------------</td>
<td>--------------------</td>
<td>-----------------------</td>
<td>---------------</td>
<td>------------------------</td>
</tr>
<tr>
<td><strong>Broad Agency Announcements</strong></td>
<td>BARDA</td>
<td>Multiple</td>
<td>Academia; Industry</td>
<td>BAA-18-100-SOL-0003</td>
<td>White paper required</td>
<td>October 31, 2019</td>
<td>&gt;&gt;$1M</td>
<td>Project-dependent</td>
</tr>
<tr>
<td><strong>DSO Office-wide Broad Agency Announcement</strong></td>
<td>DARPA</td>
<td>Multiple</td>
<td>Academia; Industry</td>
<td>HR001118S0041 (2-pg abstract suggested)</td>
<td>Abstract suggested</td>
<td>April 25, 2019</td>
<td>Project-dependent</td>
<td>6-12 mos.</td>
</tr>
<tr>
<td><strong>Congressionally Directed Medical Research Programs</strong></td>
<td>DOD</td>
<td>Multiple</td>
<td>Academia; Industry</td>
<td><a href="#">Solicitations</a></td>
<td>Preproposal</td>
<td>November 7, 2018 – January 7, 2019</td>
<td>Variable</td>
<td>Variable</td>
</tr>
<tr>
<td><strong>US Army Medical Research and Materiel Command Broad Agency Announcement for Extramural Medical Research</strong></td>
<td>DOD</td>
<td>Multiple</td>
<td>Academia; Industry</td>
<td>W81XWH18SBAA1</td>
<td>Preproposal</td>
<td>September 30, 2022</td>
<td>Variable</td>
<td>Up to 4-5 yrs</td>
</tr>
<tr>
<td><strong>SBIR/STTR</strong></td>
<td>NSF</td>
<td>Multiple</td>
<td>Academia; Industry</td>
<td>NSF 18-593 (SBIR Phase I) NSF 18-592 (STTR Phase I) SBIR/STTR Phase II SBIR/STTR Supplemental</td>
<td>N/A</td>
<td>December 4, 2018</td>
<td>$225k-$750k</td>
<td>Up to 2 yrs</td>
</tr>
</tbody>
</table>
NIH BRAIN Initiative: Development Optimization, and Validation of Novel Tools and Technologies for Neuroscience Research

Next deadline: [January 5, 2019]

PA-18-870 (STTR)  
PA-18-871 (SBIR)

$150k/up to 2 yrs [Phase I]*  
$1M/up to 3 yrs [Phase II]*

Eligible: Industry

| Topics | Development of novel neuroscience tools and technologies in order to better understand the structure and function of brain circuits  
No clinical trials allowed. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility</td>
<td>See PA-18-870; PA-18-871</td>
</tr>
<tr>
<td>Caveats</td>
<td>IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights</td>
</tr>
</tbody>
</table>

Contact information  See PA-18-870; PA-18-871 for relevant contact information

*may exceed original budget by up to 50% with appropriate justification
### NIH SBIR/STTR

**Topics**

- Clinical trials required: PA-18-573 (SBIR), PA-18-576 (STTR)
- No clinical trials allowed: PA-18-574 (SBIR), PA-18-575 (STTR)

**Eligibility**

- STTR: grantees can now submit SBIR Phase II after STTR Phase I
  - At least 40% of the work must be performed by the small business and at least 30% of the work must be performed by the single partnering research institution
- SBIR: min. of 2/3rds of the research or analytical effort carried out by small business

**Caveats**

- IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights

**Contact information**

- NIH, CDC, and FDA Awarding Component Contact Information: sbir@od.nih.gov
- 301-435-2688

See PA-18-573, PA-18-574, PA-18-575, PA-18-576 for other relevant contact information
NIH SBIR/STTR Phase IIb: Continuation of Phase II

Next deadline: [Must apply while under Phase II support]*

PA-18-573, PA-18-574 (SBIR)
PA-18-575, PA-18-576 (STTR)

$1M/yr for up to 3 yrs [Phase IIb]

Eligible: Academia; Industry

| Topics | Clinical trials required: PA-18-573 (SBIR), PA-18-576 (STTR)  
No clinical trials allowed: PA-18-574 (SBIR), PA-18-575 (STTR) |
|--------|-------------------------------------------------------------------|

<table>
<thead>
<tr>
<th>Eligibility</th>
<th>Not all agencies accept Phase IIB applications</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Eligible Agencies:</th>
</tr>
</thead>
<tbody>
<tr>
<td>NIA, NIAAA, NIAID (SBIR only), NICHD (SBIR only and only Competing Renewals of NICHD-supported Phase II awards), NIDA, NIDCD, NIDDK (only Competing Renewals of NIDDK-supported Phase II awards), NEI (SBIR only), NIGMS (SBIR only), NIMH (SBIR only), NCATS (SBIR only and only Competing Renewals of NCATS-supported Phase II awards), and ORIP (SBIR only). NCI offers Phase IIB opportunities that focus on the commercialization of SBIR developed technologies</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Caveats</th>
<th>IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Contact information</th>
<th>Phase II program officer</th>
</tr>
</thead>
</table>

*Institute/Center-specific deadlines
NIH SBIR: Tools for Cell Line Identification

Next deadline:
[January 5, 2019; April 6, 2019]
[Phase I]: $150k+/up to 6 mos. (SBIR)
or 12 mos. (STTR)*
[Phase II]: $1M+/up to 2 yrs*

Eligible: Industry

PA-16-186 (SBIR) R43/R44

Topics

Develop a solution that will address the problem of misidentified cell lines by improving existing technologies and/or developing novel, reliable and cost effective tools that will make it easier for researchers to confirm the identity and/or sex of the cells they use in their work.

Eligibility

- Applications for support of research and development of particular types of complex technologies that require funding levels and durations beyond those reflected in standard SBIR guidelines are encouraged, as are multi-PD/PI applications, including multi-PD/PI applications that arise from academic-industrial partnerships.
  - Although, as this is a SBIR, only small business concerns can submit applications.

Caveats

IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights

Contact information

See solicitation for contact information.
## NIH/NCI Cancer Moonshot Funding Opportunities

### Moonshot Solicitations

<table>
<thead>
<tr>
<th>Grant Name</th>
<th>Solicitation Link</th>
<th>LOI</th>
<th>Exp Date</th>
<th>Budget</th>
<th>Project Period</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Emerging Questions in Cancer Systems Biology</td>
<td>PAR-16-131 (U01)</td>
<td>30 days prior</td>
<td>11/24/2018</td>
<td>Not limited</td>
<td>5 yrs</td>
<td></td>
</tr>
<tr>
<td>Dissemination and Implementation Research in Health</td>
<td>PAR 16-238 (R01)</td>
<td>30 days prior</td>
<td>5/8/2019</td>
<td>Not limited</td>
<td>5 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PAR 16-236 (R21)</td>
<td></td>
<td>5/8/2019</td>
<td>$275k DC/ 2yr</td>
<td>2 yrs</td>
<td></td>
</tr>
<tr>
<td>Gene Fusions in Pediatric Sarcomas</td>
<td>PA-16-251 (R01)</td>
<td>N/A</td>
<td>5/8/2019</td>
<td>Not limited</td>
<td>5 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA-16-252 (R21)</td>
<td></td>
<td>5/8/2019</td>
<td>$275k DC/ 2yr</td>
<td>2 yrs</td>
<td></td>
</tr>
<tr>
<td>Improving Smoking Cessation in Socioeconomically Disadvantaged Populations via Scalable Interventions</td>
<td>PAR-16-202 (R01)</td>
<td>N/A</td>
<td>6/14/2019</td>
<td>Not limited</td>
<td>5 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PAR-16-201 (R21)</td>
<td></td>
<td>6/14/2019</td>
<td>$275k DC/ 2yr</td>
<td>2 yrs</td>
<td></td>
</tr>
<tr>
<td>Metabolic Reprogramming to Improve Immunotherapy</td>
<td>PAR-16-228 (R01)</td>
<td>N/A</td>
<td>9/8/2019</td>
<td>Not limited</td>
<td>5 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PAR-16-229 (R21)</td>
<td></td>
<td>9/8/2019</td>
<td>$275k DC/ 2yr</td>
<td>2 yrs</td>
<td></td>
</tr>
<tr>
<td>Research Projects to Enhance Applicability of Mammalian Models for Translational Research</td>
<td>Collaborative: PAR-17-244 (R01); General: PAR-17-245 (R01)</td>
<td>N/A</td>
<td>5/8/2020</td>
<td>$450k DC/ yr</td>
<td>5 yrs</td>
<td></td>
</tr>
</tbody>
</table>

**Caveats:** IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights
NIH/NCI SBIR: Innovative Molecular Analysis Technology Development for Cancer Research and Clinical Care

**PA-18-303 (SBIR)**

Next deadline: [January 5, 2019; April 6, 2019]

- $150k+/up to 6 months [Phase I]*
- $1M+/up to 2 yrs [Phase II]*

Eligible: Industry

**Technologies for:**

- Deciphering basic mechanisms underlying cancer initiation and progression;
- Enabling substantially improved early cancer detection and/or cancer risk assessment;
- Distinguishing, assessing, and/or monitoring cancer stage, and progression;
- Facilitating/accelerating the processes of drug discovery or development of generic approaches to improve drug delivery;
- Facilitating and/or enhancing molecular analyses in cancer epidemiology (e.g. by allowing for rigorous and/or expeditious collection of various relevant types of data);
- Sample preparation and/or processing for improved downstream analysis;
- Novel means for assessing general analyte quality to determine sample fitness-for-purpose for a known analytical platform; and
- Helping overcome various barriers in research on the incidence, prevalence, mortality, and burden of cancer among members of underserved populations.

**Topics**
| Eligibility | Min. of $100k of qualifying funds are required to apply  
- NSF will match qualifying funds 50% up to $500k  
Qualifying funds outlined in “Third Party Funding Qualifications and Use” |
| Caveats | IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights |
| Contact information | Jonathan Franca-Koh, PhD, MBA (Scientific Contact)  
National Cancer Institute  
240-276-7622  
francakahjc@mail.nih.gov |
**NIH/NHLBI SBIR/STTR Phase IIb Small Market Award**

**RFA-HL-19-018**
(Letter of Intent suggested)

Next deadline: [July 9, 2019]

Up to $3M/3 yrs*

Eligible: Academia; Industry

### Topics

Products related to the NHLBI mission that address a rare disease or young pediatric populations

### Eligibility

- To provide support to SBIR or STTR awardees developing NHLBI mission-related technologies that relate to heart, lung, blood, and sleep disorders and diseases
- Must secure third-party financing that is ≥1/3 NHLBI funds requested over entire project period
- Must be predicated on research funded by Phase II SBIR or STTR award
- Any NIH Institute or Center or any other Fed agency can apply,
- Work must relate to NHLBI mission and require Federal regulatory approval/clearance

### Caveats

IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights

### Contact information

**Gary Robinson, Ph.D.**  
National Heart, Lung, and Blood Institute (NHLBI)  
Telephone: 301-496-2149  
Email: NHLBI_SBIR@mail.nih.gov

**Lili M. Portilla, MPA**  
National Center for Advancing Translational Sciences (NCATS)  
Telephone: 301-827-7170  
Email: NCATSSBIRSTTR@mail.nih.gov
**NIH/NIAID Radiological/Nuclear Medical Countermeasure Product Development Program (SBIR)**

Next deadline: [January 5, 2019]

**PA-18-525**

$300k/yr, up to 2 yrs [Phase I]

$1M/yr, up to 3 yrs [Phase II]

Eligible: Industry

<table>
<thead>
<tr>
<th>Topics</th>
<th>Encourage new or renewal SBIR grant applications focused on product development activities for radiological/nuclear medical countermeasures leading to Investigational New Drug (IND) or Investigational Device Exemption (IDE) submission packages to the FDA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility</td>
<td>See solicitation for requirements.</td>
</tr>
<tr>
<td>Caveats</td>
<td>IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights</td>
</tr>
</tbody>
</table>
| Contact information | Carmen Rios, PhD  
Phone: 240-627-3553  
Email: carmen.rios@nih.gov |
## NIH/NIAID Resource-Related Projects

**PAR-16-412**  
(Letter of Intent suggested)

### Topics

The proposed resource must provide a significant benefit to currently funded high-priority projects in need of further coordination and support in the areas specified. Under rare circumstances, this mechanism may be used to support development of a new resource to the broader scientific community of the NIAID.

The proposed resources should be relevant to the scientific areas of the NIAID mission including the biology, pathogenesis, and host response to microbes, including HIV; the mechanisms of normal immune function and immune dysfunction resulting in autoimmunity, immunodeficiency, allergy, asthma, and transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious, immuno-mediated, and allergic diseases.

### Eligibility

See solicitation for requirements.

### Caveats

IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights.

### Contact information

**For the Division of AIDS (DAIDS):**  
Martin Gutierrez, Ph.D.  
(NIAID)  
Telephone: 240-292-4844  
Email: mgutierrez@niaid.nih.gov

**For the Division of Microbiology and Infectious Diseases (DMID):**  
Maureen Beanan, Ph.D.  
(NIAID)  
Telephone: 240-292-0999  
Email: beananm@mail.nih.gov

**For the Division of Allergy Immunology and Transplantation (DAIT):**  
Joseph J. Breen, Ph.D.  
(NIAID)  
Telephone: 240-292-4123  
Email: jbreen@niaid.nih.gov

Next deadline:  
[January 5, 2019]

Unlimited $ /up to 5 yrs

Eligible: Industry
NIH/NIAID SBIR Phase II Clinical Trial
Implementation Cooperative Agreement

PAR-16-271

Next deadline:
[January 14, 2019]
$150k+ / 1 yr [Phase I]*
$1M+ / 3 yrs [Phase II]*

Eligible: Industry

Topics

This program provides support for hypothesis-driven, milestone-driven clinical trials. Although clinical trials not considered high-risk may be proposed, this program encourages high-risk clinical studies. High-risk does not imply human subject or patient risk, but rather defines a study that contains one or more of the following unique features: involves non-routine interventions, administration of an unlicensed product, or administration of a licensed product for an unapproved indication. Mechanistic studies are also encouraged and can be proposed under this program. However, not more than one clinical trial should be proposed within each application.

Eligibility

See solicitation for requirements.

Caveats

IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights

Contact information

Michael Minnicozzi, Ph.D.
Division of Allergy, Immunology and Transplantation (DAIT)
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3532
Email: minnicozzim@niaid.nih.gov

Shy Shorer, M.D.
Division of Microbiology and Infectious Diseases (DMID)
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-627-3371
Email: ss932c@nih.gov

Martin Gutierrez
Division of Acquired Immunodeficiency Syndrome (DAIDS)
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-292-4844
Email: mgutierrez@niaid.nih.gov

* Phase I and II topics may be eligible for up to $300k (Phase I) and/or $2M (Phase II), dependent on topic; Contact Program Officer prior to exceeding budgets of $225k (Phase I) / $1.5M (Phase II)
### NIH/NINDS CREATE: Bio Optimization and Development Tracks for Biologics

| PAR-17-456 (U01) | (Optimization) | $1-4M/up to 5 yrs* |
| PAR-17-457 (U44/SBIR) |  |
| PAR-18-542 (U01) |  | Eligible: Academia; Industry |
| PAR-18-543 (U44/SBIR) |  |

#### Topics
Biotechnology product- and biologics-based therapies, which broadly include modalities such as peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging technologies

#### Eligibility
See [FOA](#) and individual solicitations

#### Caveats
IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights

#### Contact Information
- Chris Boshoff, Ph.D.
- National Institute of Neurological Disorders and Stroke (NINDS)
  
  Telephone: 301-496-1779
  
  Email: chris.boshoff@nih.gov

*Dependent on phase and grant type (optimization vs development)*
**BARDA Broad Agency Announcements**

**BAA-18-100-SOL-0003**  
(requires white paper)

| Topics | Advanced research and development of medical countermeasures for chemical, biological, radiological, nuclear agents, pandemic influenza, and emerging infectious diseases.  
Topics of interest include: CBRN vaccines, antitoxins, antibacterials, radiological/nuclear threat medical countermeasures, chemical threat medial countermeasures, burn medical countermeasures, diagnostics, influenza and emerging infectious diseases vaccines and therapeutics, ventilators, MCM platform systems, modeling as enabling technology for influenza, emerging infectious disease and CBRN threats, and visual analytics an enabling technology for influenza, emerging infectious disease and CBRN threats. |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility</td>
<td>While larger companies are convenient due to all resources being collectively held, smaller companies can still be successful if they coordinate all required resources to conduct proposed work.</td>
</tr>
</tbody>
</table>
| How to apply | **White paper**: usually 5-6 pages in length. Will be reviewed and feedback given. Can resubmit if rejected.  
**Proposal**: 6 weeks to submit proposal from white paper acceptance (can be negotiated to 10 weeks). Usually 100 pages without appendices (see solicitations for page limits). |

Next deadline(s):  
[January 31, 2019]*  
Funding amount is solicitation dependent (>>$1M)  
Eligible: Academia; Industry
| Caveats | Contract, not a grant—funds will be reimbursed to company after spent
|         | IP: fully paid, royalty-free license subject to War Powers Act |
| Contact information | Rodney Wallace, Director of Diagnostics and Med Devices Division (BARDA)
|                     | Rodney.wallace@hhs.gov |

*Deadline is rolling; submissions reviewed every 3 months.*
DARPA DSO Office-wide
Broad Agency Announcement

**Topics**
Neuroscience, psychology, cognitive science, and related topics; improving interfaces between biological and physical world; cell, tissue, organ engineering; automated platforms for biological sample collection, processing, and analysis.

**Eligibility**
See solicitation for requirements.

**Caveats**
“DARPA will have, at a minimum, Government Purpose Rights to technical data and computer software developed through mixed sponsorship.” See Solicitation for more information.

**Contact information**
BAA Coordinator
BTOBAA2018@darpa.mil

Next deadline:
[Rolling submissions until April 25, 2019]

Funding dependent on project proposal

Eligible: Academia; Industry
## DOD SBIR/STTR

<table>
<thead>
<tr>
<th>Topics</th>
<th>See <a href="https://www.dodsbir.net">website</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility</td>
<td>See solicitation for requirements.</td>
</tr>
</tbody>
</table>
| Caveats | • IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights  
• IP is reported to i-Edison site |
| Contact information | DoD SBIR/STTR Help Desk  
1-800-348-0787  
sbirhelp@bytecubed.com |

Next deadline:  
[February 6, 2019](https://www.dodsbir.net)  
(opens November 24, 2018)  
[Phase I] $70k-$150k/6-12 mo.  
[Phase II] $500k-$1M/24 mo.  
Eligible: Academia; Industry
## DOD Congressionally Directed Medical Research Programs

**Solicitations**

**Topics**

- Bone marrow failure; Breast cancer; Defense medical research and development; Duchenne muscular dystrophy; Gulf War illness; Hearing restoration; Lupus; Orthotics and prosthetics outcomes; Psychological health/traumatic brain injury; Vision.

**Eligibility**

See individual solicitations for requirements.

**Caveats**

- IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights

**Contact information**

See individual solicitations for contact information.

Next deadline: [November 7, 2018 – January 7, 2019; see individual solicitations for dates]

Awards vary

Eligible: Academia; Industry
# DOD US Army Medical Research and Materiel Command Broad Agency Announcement for Extramural Medical Research

**W81XWH18SBAA1**

<table>
<thead>
<tr>
<th>Topics</th>
<th>Programs encompassed: Combat Casualty Care Research Program, Military Operational Medicine Research Program, Clinical and Rehabilitative Medicine Research Program, Medical Biological Defense Research Program, Medical Chemical Defense Research Program, Medical Simulation and Information Sciences Research Program, Radiation Health Effects Research Program</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eligibility</td>
<td>See solicitation for requirements.</td>
</tr>
<tr>
<td>Caveats</td>
<td>• “A term of the award requires the recipient to grant the Government all necessary and appropriate licenses, which could include licenses to background and proprietary information that have been developed at private expense”</td>
</tr>
<tr>
<td>Contact information</td>
<td>CDMRP Help Desk  Phone: 301-682-5507  Email: <a href="mailto:help@eBRAP.org">help@eBRAP.org</a></td>
</tr>
</tbody>
</table>

Next deadline: [September 30, 2022]*

Unspecified amounts, up to 4 years (assistance agreements) or 5 years (contract awards)

Eligible: Academia; Industry

---

*C: Continuously open, with reviews throughout the year

**A: Awards are made to organizations only and small businesses must be given the maximum practical opportunity to participate through subawards on research proposals
<table>
<thead>
<tr>
<th>Topics</th>
</tr>
</thead>
<tbody>
<tr>
<td>Because the program has no topical or procurement focus, the NSF offers very broad solicitation topics that are intended to encourage as many eligible science- and technology-based small businesses as possible to compete for funding. The topics are detailed on the website. In many cases, the program is also open to proposals focusing on technical and market areas not explicitly noted in the aforementioned topics.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Eligibility</th>
</tr>
</thead>
</table>
| **STTR:**
Grantees can now submit SBIR Phase II after STTR Phase I
At least 40% of the work must be performed by the small business and at least 30% of the work must be performed by the single partnering research institution |

| SBIR: |
Minimum of 2/3\textsuperscript{rd}s of the research or analytical effort must be carried out by small business |

| Phase IIb: |
Min of $100k of qualifying funds are required to apply
NSF will match qualifying funds 50% up to $500k
Qualifying funds outlined in “Third Party Funding Qualifications and Use” |

<table>
<thead>
<tr>
<th>Caveats</th>
</tr>
</thead>
<tbody>
<tr>
<td>• IP developed is subject to the Bayh–Dole Act and, therefore, march-in rights.</td>
</tr>
<tr>
<td>• You can only apply once to a Phase II award.</td>
</tr>
</tbody>
</table>
Contact information  See solicitations for relevant contact information.

*Supplemental Funding (Phase IIb) deadline is 1 month prior to end of Phase II